Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | -61.50% | 0.00% | -11.52% | 0.00% |
| Total Depreciation and Amortization | 0.00% | -3.44% | 0.00% | -15.48% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | 66.42% | 0.00% | 37.38% | 0.00% |
| Change in Net Operating Assets | 0.00% | 259.81% | 0.00% | 283.03% | 0.00% |
| Cash from Operations | 0.00% | -34.16% | 0.00% | 9.63% | 0.00% |
| Capital Expenditure | 0.00% | -- | -- | 100.00% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -- | -- | 100.00% | 0.00% |
| Total Debt Issued | 0.00% | 197.49% | 0.00% | -200.00% | 0.00% |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | 0.00% | 119,010.00% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -- | -- | -- |
| Cash from Financing | 0.00% | 12.04% | 0.00% | -15.55% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | -307.25% | 0.00% | -51.95% | 0.00% |